Details of the Drug

General Information of Drug (ID: DMTGNWU)

Drug Name
Tofisopam
Synonyms
tofisopam; 22345-47-7; Grandaxin; Seriel; 1-(3,4-Dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-5H-2,3-benzodiazepine; Egyt 341; Tofisopamum; 5H-2,3-Benzodiazepine, 1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-; tofizopam; NCGC00165912-02; 1-(3,4-Dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-5H-benzo[d][1,2]diazepine; benzodiazepine; EGYT 341; Grandaxin; Nodeprine; Seriel; Tofisopamum [INN-Latin]; 7,8-Dimethoxy-1-(3,4-dimethoxyphenyl)-5-ethyl-4-methyl-5H-2,3-benzodiazepine; Tofisopam [INN:DCF:JAN]; EINECS 244-922-3; CCRIS 8738; Emandaxin (TN); DSSTox_CID_3681; Tofisopam (JP17/INN); DSSTox_RID_77145; DSSTox_GSID_23681; SCHEMBL43522; Tofisopam (patented in japan); CHEMBL404216; SCHEMBL8086894; DTXSID3023681; CHEBI:32241; BCP09600; Tox21_112269; MFCD00823171; Tofisopam, >=98% (HPLC), solid; AKOS025401672; DB08811; QC-1212; NCGC00165912-01; NCGC00165912-03; AC-24288; LS-14948; CAS-22345-47-7; DB-045872; FT-0638212; X6663; D01254; 345T477; Q945537; Q-201839; BRD-A69095630-001-01-1; 1-(3,4-dimethoxyphenyl)-4-methyl-5-ethyl-7,8-dimethoxy-5H-2,3-benzodiazepine; 1-[3,4-bis(methyloxy)phenyl]-5-ethyl-4-methyl-7,8-bis(methyloxy)-5H-2,3-benzodiazepine; (1Z,3Z)-1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-5H-benzo[d][1,2]diazepine
Indication
Disease Entry ICD 11 Status REF
Hyperuricaemia 5C55.Y Phase 2 [1]
Irritable bowel syndrome DD91.0 Phase 2 [2]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 382.5
Logarithm of the Partition Coefficient (xlogp) 3.2
Rotatable Bond Count (rotbonds) 6
Hydrogen Bond Donor Count (hbonddonor) 0
Hydrogen Bond Acceptor Count (hbondacc) 6
ADMET Property
Half-life
The concentration or amount of drug in body reduced by one-half in 6 - 8 hours [3]
Metabolism
The drug is metabolized via the hepatic []
Chemical Identifiers
Formula
C22H26N2O4
IUPAC Name
1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-5H-2,3-benzodiazepine
Canonical SMILES
CCC1C(=NN=C(C2=CC(=C(C=C12)OC)OC)C3=CC(=C(C=C3)OC)OC)C
InChI
InChI=1S/C22H26N2O4/c1-7-15-13(2)23-24-22(14-8-9-18(25-3)19(10-14)26-4)17-12-21(28-6)20(27-5)11-16(15)17/h8-12,15H,7H2,1-6H3
InChIKey
RUJBDQSFYCKFAA-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
5502
ChEBI ID
CHEBI:32241
CAS Number
22345-47-7
DrugBank ID
DB08811
TTD ID
DB82TO
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Phosphodiesterase 10A (PDE10) TTJW4LU PDE10_HUMAN Inhibitor [4]
Phosphodiesterase 2A (PDE2A) TTJGW1Z PDE2A_HUMAN Inhibitor [4]
Phosphodiesterase 3 (PDE3) TTZCG4L NOUNIPROTAC Inhibitor [4]
Phosphodiesterase 4A (PDE4A) TTZ97H5 PDE4A_HUMAN Inhibitor [4]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Hyperuricaemia
ICD Disease Classification 5C55.Y
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Phosphodiesterase 4A (PDE4A) DTT PDE4A 9.26E-01 -3.01E-03 -0.01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT01519687) Study of Levotofisopam 50 mg Three Times a Day (TID) Administered for 7 Days on Hyperuricemia and Gout. U.S. National Institutes of Health.
2 ClinicalTrials.gov (NCT00486876) A Study of 3 Doses of Dextofisopam in Females With Irritable Bowel Syndrome. U.S. National Institutes of Health.
3 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4 The atypical anxiolytic drug, tofisopam, selectively blocks phosphodiesterase isoenzymes and is active in the mouse model of negative symptoms of psychosis. J Neural Transm (Vienna). 2010 Nov;117(11):1319-25.